Therapeutic experience with fludrocortisone in diabetic postural hypotension

Area of Science:

• Endocrinology
• Cardiovascular Medicine
• Nephrology

Background:

• Diabetic postural hypotension is a common complication of diabetes mellitus.
• It significantly impacts patients' quality of life and mobility.
• Current treatment options may have limitations or side effects.

Purpose of the Study:

• To evaluate the efficacy and safety of fludrocortisone in treating diabetic postural hypotension.
• To assess the impact of fludrocortisone on blood pressure and symptomatic improvement.
• To identify potential contraindications for fludrocortisone use.

Main Methods:

• A cohort of fourteen patients with diabetic postural hypotension was enrolled.
• Patients received fludrocortisone treatment for a mean duration of 12 months.
• Dosage ranged from 0.1 mg to 0.4 mg daily, with a mean of 0.2 mg.
• Blood pressure measurements (systolic and diastolic) were taken while standing before and after treatment.

Main Results:

• Significant increases in standing systolic and diastolic blood pressures were observed (P < 0.001).
• A significant reduction in postural hypotension was documented (P < 0.001).
• Thirteen out of fourteen patients reported considerable symptomatic improvement.

Conclusions:

• Fludrocortisone is an effective treatment for diabetic postural hypotension.
• The medication leads to significant improvements in blood pressure and patient-reported symptoms.
• Cautious use is recommended in patients with congestive cardiac failure or nephrotic syndrome due to potential risks.